September 11, 2019
Daiichi Sankyo published on September 10 updated safety and efficacy data from PI studies of its investigational TROP2 targeting antibody drug conjugate (ADC) DS-1062 and its investigational HER3 targeting ADC U3-1402 in patients with non-small cell lung cancer (NSCLC) at...read more